Rosetta Genomics last month disclosed in a US Securities and Exchange Commission filing that Ronen Tamir, its chief commercialization officer, would resign to "pursue other opportunities."

Although details surrounding Tamir's departure were not provided, it comes on the heels of yet another changeup to Rosetta's overall business strategy, and the recent replacement of its president and CEO.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.